Zobrazeno 1 - 10
of 1 937
pro vyhledávání: '"Voest, E."'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Hernando-Calvo A; Department of Medical Oncology, Vall d́Hebron Barcelona Hospital Campus, Barcelona, Spain; Vall d́Hebron Institute of Oncology, Barcelona, Spain., Rossi A; Vall d́Hebron Institute of Oncology, Barcelona, Spain., Vieito M; Department of Medical Oncology, Vall d́Hebron Barcelona Hospital Campus, Barcelona, Spain; Vall d́Hebron Institute of Oncology, Barcelona, Spain., Voest E; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands; Oncode Institute, Utrecht, the Netherlands., Garralda E; Department of Medical Oncology, Vall d́Hebron Barcelona Hospital Campus, Barcelona, Spain; Vall d́Hebron Institute of Oncology, Barcelona, Spain. Electronic address: egarralda@vhio.net.
Publikováno v:
Cancer treatment reviews [Cancer Treat Rev] 2024 Jul; Vol. 128, pp. 102747. Date of Electronic Publication: 2024 Apr 27.
Autor:
Vis, D.J., Lewin, J., Liao, R.G., Mao, M., Andre, F., Ward, R.L., Calvo, F., Teh, B.T., Camargo, A.A., Knoppers, B.M., Sawyers, C.L., Wessels, L.F.A., Lawler, M. *, Siu, L.L., Voest, E.
Publikováno v:
In Annals of Oncology May 2017 28(5):1145-1151
Autor:
Battaglia TW; Division of Molecular Oncology & Immunology, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands; Division of Molecular Carcinogenesis, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands; Oncode Institute, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands., Mimpen IL; Division of Molecular Oncology & Immunology, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands; Oncode Institute, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands., Traets JJH; Division of Tumor Biology & Immunology, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands., van Hoeck A; Oncode Institute, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands; Department of Head and Neck Surgery and Oncology, the Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands., Zeverijn LJ; Division of Molecular Oncology & Immunology, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands; Oncode Institute, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands., Geurts BS; Division of Molecular Oncology & Immunology, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands; Oncode Institute, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands., de Wit GF; Division of Molecular Oncology & Immunology, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands; Oncode Institute, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands., Noë M; Department of Pathology, Antoni van Leeuwenhoek/the Netherlands Cancer Institute, Amsterdam, the Netherlands., Hofland I; Core Facility Molecular Pathology & Biobanking, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands., Vos JL; Division of Tumor Biology & Immunology, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands; Head and Neck Service and Immunogenomic Oncology Platform, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Cornelissen S; Core Facility Molecular Pathology & Biobanking, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands., Alkemade M; Core Facility Molecular Pathology & Biobanking, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands., Broeks A; Core Facility Molecular Pathology & Biobanking, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands., Zuur CL; Division of Tumor Biology & Immunology, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands; Department of Head and Neck Surgery and Oncology, the Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands; Department of Otorhinolaryngology Head and Neck Surgery, Leiden University Medical Center, Leiden, the Netherlands., Cuppen E; Center for Molecular Medicine, University Medical Centre Utrecht, Utrecht 3584CX, the Netherlands; Hartwig Medical Foundation, Science Park, Amsterdam 1098XH, the Netherlands., Wessels L; Division of Molecular Carcinogenesis, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands; Oncode Institute, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands; Faculty of EEMCS, Delft University of Technology, Delft 2628 CD, the Netherlands., van de Haar J; Division of Molecular Oncology & Immunology, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands; Oncode Institute, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands., Voest E; Division of Molecular Oncology & Immunology, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands; Oncode Institute, the Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands. Electronic address: e.voest@nki.nl.
Publikováno v:
Cell [Cell] 2024 Apr 25; Vol. 187 (9), pp. 2324-2335.e19. Date of Electronic Publication: 2024 Apr 09.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Edsjö A; Department of Clinical Genetics, Pathology and Molecular Diagnostics, Office for Medical Services, Region Skåne, Lund, Sweden.; Division of Pathology, Department of Clinical Sciences, Lund University, Lund, Sweden.; Genomic Medicine Sweden (GMS), Kristianstad, Sweden., Holmquist L; Department of Clinical Genetics, Pathology and Molecular Diagnostics, Office for Medical Services, Region Skåne, Lund, Sweden.; Genomic Medicine Sweden (GMS), Kristianstad, Sweden., Geoerger B; Department of Pediatric and Adolescent Oncology, Gustave Roussy Cancer Campus, Université Paris-Saclay, Villejuif, France.; INSERM U1015, Gustave Roussy Cancer Campus, Université Paris-Saclay, Villejuif, France., Nowak F; Health Technologies Institute, Inserm, Paris, France., Gomon G; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.; Department of Medical Oncology, Leiden University Medical Centre, Leiden, The Netherlands., Alix-Panabières C; Laboratory of Rare Human Circulating Cells, University Medical Center of Montpellier, Montpellier, France.; CREEC, MIVEGEC, University of Montpellier, Montpellier, France., Ploeger C; Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.; Centers for Personalized Medicine (ZPM), Heidelberg, Germany., Lassen U; Department of Oncology, Copenhagen University Hospital, Copenhagen, Denmark., Le Tourneau C; Department of Drug Development and Innovation (D3i), Institut Curie, Paris, France.; INSERM U900 Research Unit, Saint-Cloud, France.; Faculty of Medicine, Paris-Saclay University, Paris, France., Lehtiö J; Department of Oncology Pathology, Karolinska Institutet, Science for Life Laboratory, Stockholm, Sweden., Ott PA; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA., von Deimling A; Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Neuropathology, Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany., Fröhling S; Division of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg and German Cancer Research Center (DKFZ), Heidelberg, Germany.; German Cancer Consortium (DKTK), Heidelberg, Germany., Voest E; Department of Molecular Oncology and Immunology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.; Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Klauschen F; Institute of Pathology, Charite - Universitätsmedizin Berlin, Berlin, Germany.; German Cancer Consortium (DKTK), Partner Site Berlin, and German Cancer Research Center (DKFZ), Heidelberg, Germany.; BIFOLD - Berlin Institute for the Foundations of Learning and Data, Berlin, Germany.; Institute of Pathology, Ludwig-Maximilians-University, Munich, Germany.; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Munich Partner Site, Heidelberg, Germany., Dienstmann R; Oncoclínicas Precision Medicine, Oncoclínicas Group, Sao Paulo, Brazil., Alshibany A; Princess Margaret Cancer Centre, Toronto, Ontario, Canada., Siu LL; Princess Margaret Cancer Centre, Toronto, Ontario, Canada., Stenzinger A; Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.; Centers for Personalized Medicine (ZPM), Heidelberg, Germany.
Publikováno v:
Journal of internal medicine [J Intern Med] 2023 Oct; Vol. 294 (4), pp. 455-481. Date of Electronic Publication: 2023 Aug 28.
Autor:
Voest E; Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Publikováno v:
Clinical advances in hematology & oncology : H&O [Clin Adv Hematol Oncol] 2023 Sep (9), pp. 471-473.